Leerink Partnrs Has Negative Outlook of KROS FY2024 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for Keros Therapeutics in a report issued on Thursday, November 7th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($5.26) for the year, down from their previous forecast of ($4.76). The consensus estimate for Keros Therapeutics' current full-year earnings is ($5.14) per share. Leerink Partnrs also issued estimates for Keros Therapeutics' Q4 2024 earnings at ($1.36) EPS, FY2025 earnings at ($5.84) EPS, FY2026 earnings at ($6.58) EPS, FY2027 earnings at ($3.79) EPS and FY2028 earnings at $1.48 EPS.

KROS has been the subject of several other research reports. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Thursday. Bank of America cut their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research note on Thursday, September 12th. Guggenheim assumed coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a "buy" rating and a $96.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating for the company. Finally, Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an "overweight" rating for the company. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics currently has a consensus rating of "Buy" and an average target price of $88.89.

Keros Therapeutics Trading Up 0.4 %

KROS stock traded up $0.24 on Monday, hitting $68.15. The company had a trading volume of 422,580 shares, compared to its average volume of 370,804. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of -13.08 and a beta of 1.23. The stock's 50-day simple moving average is $58.19 and its 200 day simple moving average is $52.13. Keros Therapeutics has a 12-month low of $27.31 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm's revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period in the previous year, the company earned ($1.33) EPS.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently made changes to their positions in KROS. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 1.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company's stock valued at $870,000 after buying an additional 251 shares during the period. GSA Capital Partners LLP boosted its holdings in shares of Keros Therapeutics by 25.5% in the first quarter. GSA Capital Partners LLP now owns 8,538 shares of the company's stock valued at $565,000 after purchasing an additional 1,736 shares during the period. Swiss National Bank grew its stake in Keros Therapeutics by 22.0% in the first quarter. Swiss National Bank now owns 49,900 shares of the company's stock worth $3,303,000 after purchasing an additional 9,000 shares in the last quarter. ProShare Advisors LLC increased its holdings in Keros Therapeutics by 26.5% during the 1st quarter. ProShare Advisors LLC now owns 7,136 shares of the company's stock worth $472,000 after purchasing an additional 1,496 shares during the period. Finally, Vanguard Group Inc. raised its position in Keros Therapeutics by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company's stock valued at $102,329,000 after purchasing an additional 113,563 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the firm's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares in the company, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 22.90% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.